PEPTIDEREPORT

Primary regulatory

Rapamune (sirolimus) Label Information

FDA-approved prescribing label for Rapamune (sirolimus), indicated for prophylaxis of organ rejection in kidney transplant patients and for the treatment of lymphangioleiomyomatosis (LAM).

U.S. Food and Drug AdministrationPublished 2023-09-01Accessed 2026-07-01

Open original source

Registry record

Source metadata

Publisher
U.S. Food and Drug Administration
Source type
Primary regulatory
Registry ID
fda-rapamune-label

Source usage

Linked from 3 pages

Evidence curation

Best Compounds for Longevity Research

Guide

Peptide Category Explainers: How Every Compound Class on This Site Is Defined

Guide

Peptide Half-Life Reference Table

Interpretation boundary

What this record can and cannot establish

Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.